Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Conclusions Vorolanib can safely be combined with everolimus. Encouraging activity is seen in RCC and NET. Further studies are warranted.Trial Registration Number: NCT01784861.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Investigational New Drugs | Kidney Cancer | Neurology | Oral Cancer | Renal Cell Carcinoma | Study | Toxicology